Jump to content

Phil Oliver

  • Content Count

  • Joined

  • Last visited

Community Reputation

4 Neutral

Recent Profile Visitors

The recent visitors block is disabled and is not being shown to other users.

  1. https://www.lifespan.io/news/rick-kiessig-discusses-vtose-a-broad-spectrum-antiviral/
  2. We don't have the staggeringly massive overhead of big pharma, and we're not interested in creating drugs which merely suppress viral infections for decades at a high monthly cost, as they are. It's too early to say what the ultimate cost can be, but - assuming, of course, proof of efficacy and safety in humans - we expect that it will be affordably priced for a large number of individuals.
  3. To add to what Rick said: it's true that it cannot be patented, but it's also true that there are many other potentially patentable aspects that become evident after investigating it deeply, as we have.
  4. That's very interesting, I'll read more about that. One thing I'd note is that not every viral infection is going to be hitting the brain. Another is that VTose would not be continuously administered. It would only affect virally infected brain cells during the administration time. However, this is certainly an area that will need further thought over time and perhaps modifications to the molecule so that it doesn't pass through the blood-brain barrier.
  5. It's not the case that killing infected neurons is undesirable. An ideal example is probably rabies. The viruses traverse the peripheral nervous system, and then into the central nervous system, and ultimately into the brain with 100% mortality rate (unless stopped in time by administration of the vaccine.) Killing any infected neurons is the only way to stop the infection, and it's what a vaccine activated immune system response will do (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6790004).
  6. That's great Patrik, thanks!
  • Create New...